Protalix BioTherapeutics, Inc.
AMEX: PLX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dror Bashan
- Employees
- 231
- Headquarters
- Hackensack, United States
- IPO year
- 1998
- Market cap
- $185.3M
- Website
- https://www.protalix.com
Loading PLX…
Loading profile data…Frequently asked questions about PLX
What does Protalix BioTherapeutics, Inc. (PLX) do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with...
Where does PLX trade?
Protalix BioTherapeutics, Inc. (PLX) trades on the New York Stock Exchange Arca.
What sector is PLX in?
Protalix BioTherapeutics, Inc. (PLX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Protalix BioTherapeutics, Inc.?
Dror Bashan is the chief executive officer of Protalix BioTherapeutics, Inc. (PLX).
Where is Protalix BioTherapeutics, Inc. headquartered?
Protalix BioTherapeutics, Inc. is headquartered in United States.
Does PLX pay a dividend?
Protalix BioTherapeutics, Inc. (PLX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PLX go public?
Protalix BioTherapeutics, Inc. (PLX) completed its initial public offering in 1998.